Dov A. Goldstein M.D. is Director at Esperion Therapeutics, Inc. (ESPR). They have made 13 open-market trades across 6 companies since 2012, most recently 2026-04-23.
CIK 0001120478
7 open-market purchases totalling $26.1M since 2012, against 6 sales. Across 6 scored buys the stock is down 11.9% at ninety days, and 15.9 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 17% | 0% | 0% |
| Avg Move | -18.3% | -6.5% | -11.9% |
| Alpha | -15.9% | -8.7% | -15.9% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BIOA | SELL | 2026-01-13 | 2026-01-15 | $19.70 | $532K | -8.3% | -7.7% | -20.2% |
| NBSE | BUY | 2021-06-18 | 2021-06-21 | $4.75 | $38K | -3.6% | -18.6% | -23.1% |
| NBSE | BUY | 2021-04-26 | 2021-04-27 | $5.00 | $60K | -11.9% | -11.2% | -37.3% |
| NBSE | BUY | 2020-04-30 | 2020-05-04 | $6.00 | $60K | +1.0% | -2.8% | -4.7% |
| ESPR | SELL | 2017-03-21 | 2017-03-23 | $41.66 | $66.7M | -10.9% | -7.4% | +1.1% |
| CEMP | SELL | 2017-03-07 | 2017-03-09 | $3.56 | $533K | +14.1% | +8.5% | +9.9% |
| CEMP | SELL | 2017-01-13 | 2017-01-18 | $3.40 | $359K | +0.0% | +4.7% | +14.1% |
| CEMP | SELL | 2017-01-05 | 2017-01-06 | $3.41 | $3.2M | -14.7% | -16.0% | +2.7% |
| CEMP | SELL · 10b5-1 | 2016-01-04 | 2016-01-06 | $30.06 | $25K | -16.7% | -17.2% | -18.8% |
| CEMP | SELL · 10b5-1 | 2015-06-22 | 2015-06-24 | $35.74 | $1.8M | -36.6% | -4.1% | -4.1% |
| ESPR | SELL | 2015-04-23 | 2015-04-27 | $108.22 | $23.5M | -35.3% | -0.8% | -0.8% |
| LOXO | BUY | 2014-08-06 | 2014-08-06 | $13.00 | $5.4M | -23.5% | -1.3% | -1.3% |
| ESPR | BUY | 2013-07-01 | 2013-07-01 | $14.00 | $3.3M | -35.3% | -0.8% | -0.8% |
| DRTX | BUY | 2012-07-24 | 2012-07-25 | $9.00 | $10.0M | N/A | N/A | N/A |
| CEMP | BUY | 2012-02-07 | 2012-02-09 | $6.00 | $7.3M | -36.6% | -4.1% | -4.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| PrivateUnlisted |
| 2,516,855 |
| — |
| DRTX | 3,130,824 | — |
| Total | $16.3M |
Shares reported on the most recent Form 4, priced at the 2026-04-24 close. 2 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.